NZ748502A - Oxaborole esters and uses thereof - Google Patents

Oxaborole esters and uses thereof

Info

Publication number
NZ748502A
NZ748502A NZ748502A NZ74850217A NZ748502A NZ 748502 A NZ748502 A NZ 748502A NZ 748502 A NZ748502 A NZ 748502A NZ 74850217 A NZ74850217 A NZ 74850217A NZ 748502 A NZ748502 A NZ 748502A
Authority
NZ
New Zealand
Prior art keywords
methyl
oxaborole
valinate
dihydrobenzo
carbonyl
Prior art date
Application number
NZ748502A
Inventor
Tsutomu Akama
David Scott Carter
Jason S Halladay
Robert T Jacobs
Yang Liu
Jacob J Plattner
Yong-Kang Zhang
Michael John Witty
Original Assignee
Anacor Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anacor Pharmaceuticals Inc filed Critical Anacor Pharmaceuticals Inc
Priority claimed from NZ746906A external-priority patent/NZ746906A/en
Publication of NZ748502A publication Critical patent/NZ748502A/en

Links

Abstract

Trypanosomatids are a group of kinetoplastid protozoa distinguished by having only a single flagellum. Trypanosomatids are responsible for diseases such as South American trypanosomiasis (Chagas Disease) and African Animal Trypanosomosis (AAT). Trypanosomosis has a major economic impact on cattle production in Africa and, if untreated, generally results in chronic illness with high mortality. In the absence of vaccines, control of this disease has for long been focused on chemotherapy and vector control. The present invention provides certain oxaborole ester compounds and compositions thereof which are useful to treat diseases associated with parasites, such as African Animal Trypanosomosis. In particular, the present invention provides a compound selected from the group consisting of: (6-(Trifluoromethyl)pyridin-3-yl)methyl (1-hydroxy-7-methyl-1,3-dihydrobenzo[c][1,2]oxaborole-6-carbonyl)-L-valinate; 4-Fluorobenzyl (1-hydroxy-7-methyl-1,3-dihydrobenzo[c][1,2]oxaborole-6-carbonyl)-L-valinate; and, 4,4- Difluorocyclohexyl (1-hydroxy-7-methyl-1,3-dihydrobenzo[c][1,2]oxaborole-6-carbonyl)-L-valinate; Tetrahydro-2H-pyran-4-yl (1-hydroxy-7-methyl-1,3-dihydrobenzo[c][1,2]oxaborole-6-carbonyl)-L-valinate; and, a pharmaceutically acceptable salt thereof. Also provided is the use of a compound selected from the group consisting of: (6-(Trifluoromethyl)pyridin-3-yl)methyl (1-hydroxy-7-methyl-1,3-dihydrobenzo[c][1,2]oxaborole-6-carbonyl)-L-valinate; 4-Fluorobenzyl (1-hydroxy-7-methyl-1,3-dihydrobenzo[c][1,2]oxaborole-6-carbonyl)-L-valinate; and, 4,4- Difluorocyclohexyl (1-hydroxy-7-methyl-1,3-dihydrobenzo[c][1,2]oxaborole-6-carbonyl)-L-valinate; Tetrahydro-2H-pyran-4-yl (1-hydroxy-7-methyl-1,3-dihydrobenzo[c][1,2]oxaborole-6-carbonyl)-L-valinate; and, a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating a parasitic infection in a subject.
NZ748502A 2016-05-12 2017-05-01 Oxaborole esters and uses thereof NZ748502A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662335565P 2016-05-12 2016-05-12
NZ746906A NZ746906A (en) 2016-05-12 2017-05-01 Oxaborole esters and uses thereof

Publications (1)

Publication Number Publication Date
NZ748502A true NZ748502A (en) 2020-06-26

Family

ID=72291342

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ748502A NZ748502A (en) 2016-05-12 2017-05-01 Oxaborole esters and uses thereof

Country Status (1)

Country Link
NZ (1) NZ748502A (en)

Similar Documents

Publication Publication Date Title
CL2019002204A1 (en) HIV inhibitor compounds.
CL2020000886A1 (en) 1-Benzyl-2-imino-4-phenyl-5-oxoimidazolidine derivatives as hiv protease inhibitors.
PH12020550881A1 (en) Substituted bicyclic heterocyclic compounds as prmt5 inhibitors
SG10201811384TA (en) Mnk inhibitors and methods related thereto
PH12016501600A1 (en) 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease
EA201691803A1 (en) HUMAN PLASMA KALLIKREIN INHIBITORS
MX2020001757A (en) Compounds, salts thereof and methods for treatment of diseases.
PH12017500829A1 (en) 2-amino-3,5-difluoro-3,6-dimethyl-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors for treating alzheimer's disease
NZ700761A (en) Salt form of a human histone methyltransferase ezh2 inhibitor
BR112019006047A2 (en) compounds, one or two or more compounds, pharmaceutically acceptable salt, methanesulfonate salt, ret kinase inhibitor, medicament, uses of the compound and a compound, methods for treating or preventing cancer and for treating or preventing cancer in an individual, and, composition pharmaceutical
MX2019012884A (en) Combination therapy.
PH12017500841A1 (en) 2-amino-6-(difluoromethyl)- 5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors
PH12016502103A1 (en) Novel disubstituted 1,2, 4-triazine compound
MX2014004814A (en) Compounds and methods for enhancing innate immune responses.
PH12019502150A1 (en) Compounds and methods for the treatment of parasitic diseases
BR112019001457A2 (en) treatment and prevention of sleep disorders
JOP20190233A1 (en) Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase
NZ726695A (en) Gls1 inhibitors for treating disease
NZ746906A (en) Oxaborole esters and uses thereof
WO2016004413A3 (en) Gls1 inhibitors for treating disease
PH12019500618A1 (en) Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease
EA035519B9 (en) 1,3,4-thiadiazole compounds and their use in treating cancer
PH12018501646A1 (en) Compositions and methods for treating infections
MX2018011592A (en) Compound having mutant idh inhibitory activity, preparation method and use thereof.
MX2019006942A (en) Non-peptide oxytocin receptor agonists.

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 MAY 2022 BY THOMSON REUTERS

Effective date: 20210403

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 MAY 2023 BY THOMSON REUTERS

Effective date: 20220402

LAPS Patent lapsed